Purpose: To evaluate time trends in the incidence and prevalence of neovascular age-related macular degeneration (nAMD) and its treatments, associated factors, and effects on vision in Finland during 2000-2017.
Methods: We used three nationwide health examination surveys representing the Finnish population aged 30 years or older. All three surveys were linked to the national care register covering nAMD diagnoses and intravitreal injections between 2000 and 2017.
Background/aim: This study evaluated the diagnostic accuracy (DA) for colorectal adenomas (CRA), screened by fecal immunochemical test (FIT), using five artificial intelligence (AI) models: logistic regression (LR), support vector machine (SVM), neural network (NN), random forest (RF), and gradient boosting machine (GBM). These models were tested together with clinical features categorized as low-risk (lowR) and high-risk (highR).
Patients And Methods: The colorectal neoplasia (CRN) screening cohort of 5,090 patients included 222 CRA patients and 264 non-CRA patients.
Background: New biomarkers that improve diagnosis of Alzheimer's disease (AD) are warranted. Tear fluid (TF) containing variety of proteins that reflect pathophysiological changes of systemic diseases makes TF proteins potential biomarker candidates for AD.
Objective: We investigated the expression levels of TF proteins in persons with mild AD and cognitively healthy controls (CO) to find out if altered proteins may link to the AD pathophysiology.
Purpose: Localized diseases can be affected by and affect the systemic environment via blood circulation. In this study, we explored the differences in circulating serum mRNAs between patients with wet AMD (wAMD) and controls.
Methods: Blood samples were obtained from 60 Finnish patients with wAMD and 64 controls.
Background: Hearing impairment is a known risk factor for Alzheimer's disease (AD), although less is known about vision impairment or dual sensory impairment (DSI) as risk factors for AD. We studied the association between diagnosed hearing impairment, visual impairment, or DSI, and the risk of AD.
Method: The Medication use and Alzheimer's disease study (MEDALZ) is a register-based nested case-control study including 70,718 community-dwelling persons diagnosed with incident AD in 2005-2011 in Finland and their 282,845 matched controls.